The CXCR3 ligand signature (CXCL9/10/11) often correlated with validated measures of both disease activity, clinical measures and fibrotic load (collagen deposition) in LS patients [48,68,69,70]. This evidence concerns the gene CXCL9 and Leigh syndrome.